Pathophysiological and translational implications of the dysregulation of molecular machineries controlling RNA...

Area of Science:

• Endocrinology
• Molecular Biology
• Genetics

Background:

• Thyrotropin-secreting pituitary tumors (TSHomas) cause central hyperthyroidism, but post-transcriptional regulation is poorly understood.
• Key RNA metabolism pathways like spliceosome, RNA-exosome, and nonsense-mediated decay (NMD) are implicated in various cancers but not well-studied in TSHomas.

Purpose of the Study:

• To investigate the post-transcriptional regulatory landscape in TSHomas.
• To analyze the association of RNA metabolism components with clinical features.
• To evaluate the impact of pharmacological inhibition of these pathways in TSHoma cells.

Main Methods:

• Analysis of spliceosome, RNA-exosome, and NMD pathway components in TSHomas versus non-tumor pituitary tissues.
• Correlation of molecular alterations with clinical parameters (e.g., tumor size, hormone levels).
• Assessment of the antiproliferative effects of pathway inhibitors on patient-derived TSHoma cells.

Main Results:

• Significant dysregulation of spliceosome (e.g., SF3B2, U2AF35), RNA-exosome (e.g., DIS3, PABPN1), and NMD (e.g., PABPC1) components was observed in TSHomas.
• Specific alterations correlated with clinical features like tumor size and TSHB/fT4 levels.
• Inhibitors targeting spliceosome, RNA-exosome, and NMD pathways demonstrated significant antiproliferative activity in TSHoma cells.

Conclusions:

• TSHomas exhibit clinically relevant molecular dysregulation associated with RNA metabolism pathways.
• Inhibition of spliceosome, RNA-exosome, and NMD pathways offers potential therapeutic strategies for TSHomas.
• These pathways represent promising targets for novel diagnostic/prognostic biomarkers and treatments for TSHomas.